Back to Gene
PMM2 gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

PMM2 gene

The PMM2 gene provides instructions for creating an enzyme critical to glycosylation, a process that modifies proteins to enable their proper function in the body.

Normal Function

The PMM2 gene provides instructions for making an enzyme called phosphomannomutase 2 (PMM2). This enzyme is involved in glycosylation, a process that attaches groups of sugar molecules (oligosaccharides) to proteins, allowing them to perform a wider variety of functions.

In an early step of glycosylation, the PMM2 enzyme converts a molecule called mannose-6-phosphate to mannose-1-phosphate. This is subsequently converted into GDP-mannose, which transfers mannose to the growing oligosaccharide chain. Once the correct number of sugar molecules are linked, the oligosaccharide is attached to a protein.

Health Conditions Related to Genetic Changes

PMM2-congenital disorder of glycosylation

More than 115 mutations in the PMM2 gene cause PMM2-congenital disorder of glycosylation (PMM2-CDG, also known as congenital disorder of glycosylation type Ia). This is a severe condition characterized by:

  • Developmental delay
  • Weak muscle tone (hypotonia)
  • Abnormal distribution of fat
  • Various other signs and symptoms

All known mutations appear to result in reduced enzyme activity. This leads to a shortage of GDP-mannose within cells, meaning there is not enough activated mannose to form oligosaccharides. Consequently, glycosylation cannot proceed normally, and the production of abnormally glycosylated proteins in many organs and tissues leads to the signs and symptoms of the disorder.

Genomic Location

The PMM2 gene is found on chromosome 16.

Frequently Asked Questions

PMM2-CDG is a severe, multi-system disorder. In infants and young children, key symptoms that should raise suspicion include significant developmental delay (affecting motor skills, speech, and cognition), weak muscle tone (hypotonia), and an unusual distribution of fat, often described as "fat pads" over the buttocks. Other common signs can include inverted nipples, strabismus (crossed eyes), liver dysfunction, seizures, and problems with blood clotting. A combination of these features often points towards a congenital disorder of glycosylation.
PMM2-CDG is diagnosed through a combination of clinical evaluation and laboratory tests. Initial screening often involves a transferrin isoelectric focusing test, which can detect abnormal glycosylation patterns in the blood. If this test is abnormal, genetic testing of the PMM2 gene is performed to confirm the diagnosis by identifying specific mutations. PMM2-CDG is inherited in an autosomal recessive pattern, meaning a child must inherit two mutated copies of the PMM2 gene (one from each parent) to develop the condition. Parents are typically unaffected carriers.
Currently, there is no cure for PMM2-CDG, and treatment is primarily supportive and focused on managing symptoms and improving quality of life. This often involves a multidisciplinary approach, including physical therapy, occupational therapy, and speech therapy to address developmental delays and hypotonia. Nutritional support may be needed for feeding difficulties. Regular monitoring of organ function (liver, kidneys, heart) and management of complications like seizures or clotting issues are also crucial. Research into potential therapies, including mannose supplementation, is ongoing but not yet a standard treatment.
Families of children with PMM2-CDG can expect a need for comprehensive, lifelong care involving a team of specialists, including neurologists, developmental pediatricians, gastroenterologists, ophthalmologists, and geneticists. Regular follow-up appointments are essential to monitor the progression of symptoms and manage complications. Support groups and patient advocacy organizations can provide valuable resources, emotional support, and connect families with others facing similar challenges. Early intervention programs and educational support are also vital to help children reach their full potential.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA